Renal thrombotic microangiopathy associated with anticardiolipin antibodies in hepatitis C-positive renal allograft recipients

• Published in: Journal of the American Society of Nephrology 1999, Vol.10 (1), p.146-153
• Main Authors: BAID, S, PASCUAL, M, WILLIAMS, W. W, TOLKOFF-RUBIN, N, JOHNSON, S. M, COLLINS, B, CHUNG, R. T, DELMONICO, F. L, COSIMI, A. B, COLVIN, R. B
• Format: Article
• Language: English
• Subjects: Adult; Antibodies, Anticardiolipin - blood; Biological and medical sciences; Female; Hemolytic-Uremic Syndrome - blood; Hepatitis C - blood; Hepatitis C - complications; Hepatitis C - virology; Humans; Kidney - blood supply; Kidney - immunology; Kidney Transplantation - adverse effects; Male; Medical sciences; Microcirculation - pathology; Middle Aged; Nephrology. Urinary tract diseases; Nephropathies. Renovascular diseases. Renal failure; Renal Artery - immunology; Renovascular diseases; Venous Thrombosis - blood; Venous Thrombosis - etiology; Venous Thrombosis - therapy
• ISSN: 1046-6673; 1533-3450
• DOI: 10.1681/ASN.V101146

Hepatitis C virus (HCV) infection has been associated with de novo or recurrent membranoproliferative glomerulonephritis and acute transplant glomerulopathy in transplanted kidneys. Recently, anticardiolipin antibodies (ACA) have been linked with chronic HCV infection. A few reports have suggested an association between ACA and renal allograft thrombosis. This study examines the clinical and pathologic features of HCV-positive renal allograft recipients at our institution. From 1990 to 1996, 379 kidney transplants were performed. We identified 18 recipients (4.8%) with HCV-positive serology pretransplant. Determination of IgG and IgM ACA was performed by enzyme-linked immunosorbent assay, using pretransplant sera. Among the 18 patients, five patients presented with biopsy-proven de novo renal thrombotic microangiopathy (RTMA), occurring 5 to 120 d (median, 14 d) after transplant. No differences in pretransplant characteristics were observed between patients with (n = 5) or without (n = 13) RTMA. All five patients had a positive ACA test (either IgG or IgM titer > 2 SD above normal), compared with only one of 13 patients without RTMA. The mean value for IgG ACA was significantly higher in the RTMA patients than in patients without RTMA (22.9 +/- 14.1 versus 6.9 +/- 4.9 IgG phospholipid units, P = 0.02); however, there were no significant differences in IgM ACA titers. Rheumatoid factor and complement C4 levels were normal in pretransplant sera of patients with RTMA. Patients with RTMA had their cyclosporine withdrawn (four of five) or the dose was decreased (one of five), and one of five underwent plasmapheresis. Four of five patients died within 5 yr after transplant, compared with no deaths in the other 13 patients. Finally, as a control group, seven HCV-negative renal allograft recipients who presented with RTMA/hemolytic uremic syndrome during the same time period were found to have normal ACA values (IgG or IgM). RTMA associated with ACA in HCV-positive renal allograft recipients may represent a new clinical entity. The occurrence of this syndrome may have deleterious consequences for patient and graft survival.